The milestone payment and Phase 3 initiation de-risk the elritercept program and provide a near-term capital return catalyst via the 25% distribution. Monitor for timing of payment receipt and any subsequent updates on trial enrollment or additional milestones from Takeda.
Drug in focus
KROS drug pipeline →elritercept
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 3 (MDS); Phase 3 planned (myelofibrosis)
- Time to market
- Unknown — several years: the Phase 3 ELRiSE MDS trial (elritercept vs epoetin alfa in low-risk MDS) only began dosing patients in July 2026, and the myelofibrosis Phase 3 is planned but not yet underway; no regulatory filing or PDUFA exists.
- Next catalyst
- None dated
What to watchWatch KROS's Q2 2026 earnings (before market open, Aug 4, 2026) and any timing update on the 25% shareholder distribution of the $20M Takeda milestone. The next real value inflection, a Phase 3 readout, is years out, so near-term moves will be driven by Takeda milestones, financing/dilution news (no approved product; cash burn continuing), and execution on the ELRiSE MDS enrollment.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 31 $10.07entry
- T+1 · 4mo ago +0.40%α −1.03% · $10.11
- T+5 · 3mo ago +10.72%α +7.21% · $11.15
- T+20 · 3mo ago +9.53%α +6.55% · $11.03
- T+60 · 22d ago +12.51%α +10.06% · $11.33
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Keros Therapeutics announced a $20 million development milestone payment from partner Takeda triggered by dosing the first patient in the Phase 3 ELRiSE MDS trial for elritercept. The company expects to distribute 25% of the net cash proceeds from this milestone to stockholders, providing a tangible near-term capital return catalyst.
Key Facts
- $20 million development milestone payment from Takeda triggered by first patient dosed in Phase 3 ELRiSE MDS trial
- Phase 3 trial (ELRiSE MDS) is a multicenter, open-label, randomized study comparing elritercept vs epoetin alfa in low-risk MDS
- Keros expects to distribute 25% of net cash proceeds from this milestone to stockholders
- Under the global license agreement (effective Jan 16, 2025), Keros received $200M upfront in Feb 2025 and is eligible for up to $1.1B+ in milestones plus tiered royalties
Financial Impact
$20 million milestone payment (~10% of $197M market cap); 25% of net proceeds to be distributed to shareholders
Risk Factors
- Clinical trial risk: Phase 3 ELRiSE MDS may fail to meet endpoints
- Dependence on Takeda partnership for development and commercialization
- No approved products; pre-revenue stage with ongoing operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000043 |
| Exhibit: exhibit99173026pr.htm | 0001664710-26-000043 |
| Document: 0001664710-26-000043-index-headers.html | 0001664710-26-000043 |
| Document: 0001664710-26-000043-index.html | 0001664710-26-000043 |
| Document: 0001664710-26-000043.txt | 0001664710-26-000043 |
Track record
27 reports on KROS
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +7.84% at T+20 after the Mar 9, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers